孟鲁司特联合小剂量吸入型糖皮质激素治疗咳嗽变异性哮喘观察

目的探讨应用孟鲁司特联合小剂量吸入型糖皮质激素治疗咳嗽变异性哮喘（CVA）的疗效。方法选取CVA患者84例，分为观察组42例和对照组42例。对照组患者给予吸入型糖皮质激素布地奈德治疗，并于必要时使用β2受体激动剂。观察组在对照组治疗的基础上给予孟鲁司特。并观察两组临床疗效，复发情况以及各项肺功能指标。结果对照组单用糖皮质激素的总有效率为73．8％，观察组联合用药治疗的总有效率为95．0％，观察组的总有效率要明显高于对照组（X2=6．46，P〈0．05）。两组患者治疗前后肺功能指标比较，观察组患者的肺功能相比于对照组有显著提高（t=2．873，P〈0．05）。结论孟鲁司特联合小剂量吸入型糖皮质激素治疗咳嗽变异性哮喘能有效的提高治愈率，减少复发，可以广泛应用于临床。

Observation of montelukast combined with small dose of inhaled corticosteroid in the treatment of cough variant asthma

Objective To study the curative effect of combing montelukast with inhaled corticosteroids in the treatment of cough variant asthma. Methods According to ＂diagnosis standard guideline for diagnosis and treatment of cough in CVA＂ ,84 cases of CVA patients were chosen and divided into the treatment group （n = 42）and the control group（ n =42）. The control group were treated with inhaled corticosteroid Budesonide. The treatment group was given monelukast based on the treatment in control group. And the clinical effects of two groups, recurrence and the lung function index were observed. Results The total efficiency of treatment of the control group was 73.8%, and the treatment group was 95.0%. The total effective rate of observation group was apparently higher than that of the control group （ X2 = 6.46, P 〈 0.05 ）. The lung function of the treatment group compared to the control group was significantly increased（t = 2. 873,P 〈 0.05 ）. Conclusion Montelukast combined with Glucocorticoid in the treatment of CVA can effectively improve the cure rate, reduce the recurrence, which can be widely used in clinical treatment.